Exalenz Bioscience Ltd. develops and commercializes advanced systems that extract vital information for diagnostics from subtle changes in the patient's exhaled breath. Our proprietary core technology enables medical specialists to identify and manage specific digestive and liver conditions with unprecedented ease, patient comfort, and clinical precision.
The company's flagship product, the BreathID® System, answers a long-standing need for fast, convenient and accurate assessment and monitoring of functional diseases of the liver and gastrointestinal tract. It measures parts-per-million changes in the molecular 13C/12C ratio of the patient's exhaled breath - continuously, automatically and in real time. The BreathID System is mobile and user-friendly, and can be operated in any clinical setting.
The design of sophisticated diagnostic systems that are simple to operate is a hallmark of Exalenz. The company conducts ongoing research in collaboration with leading clinical and industrial partners in the U.S., Europe, Asia, and Israel.
The Exalenz Vision
Exalenz’ mission is to become a leading provider of accurate, breath test-based, point-of-care disease management solutions for a broad range of GI and liver disorders.
As our name implies, we define "excellence" as successfully meeting patient and practitioner needs. Our technology furthers this goal by providing both medical professionals and patients with advanced solutions and vital diagnostic information.